Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8IVJ1
UPID:
S41A1_HUMAN
Alternative names:
-
Alternative UPACC:
Q8IVJ1; Q63HJ4; Q658Z5; Q659A4; Q6MZK2
Background:
Solute carrier family 41 member 1 (SLC41A1) is a critical Na(+)/Mg(2+) ion exchanger, predominantly facilitating Mg(2+) efflux at the plasma membrane. Its activity is essential for maintaining cellular Mg(2+) homeostasis, influenced by the extracellular Na(+) concentration. SLC41A1 generates circadian Mg(2+) fluxes, impacting clock-controlled gene expression and metabolism, thus supporting higher energy demands during the day. It also plays a role in regulating ATP-dependent enzymes, crucial for metabolic processes like the Krebs cycle and the electron transport chain.
Therapeutic significance:
SLC41A1's involvement in Nephronophthisis-like nephropathy 2, a disorder leading to end-stage renal failure, underscores its therapeutic potential. Understanding the role of SLC41A1 could open doors to potential therapeutic strategies for managing this renal disorder and possibly other related metabolic dysfunctions.